Recent News

• 05.08.2025 - Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.08.2025 - Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 04.30.2025 - Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
• 04.30.2025 - Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
• 04.16.2025 - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
• 04.16.2025 - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.11.2025 - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
• 03.11.2025 - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Recent Filings

• 04.29.2025 - ARS Annual Report to Security Holders
• 04.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.29.2025 - DEF 14A Other definitive proxy statements
• 04.25.2025 - 8-K Current report
• 04.21.2025 - EFFECT Notice of Effectiveness
• 04.16.2025 - EFFECT Notice of Effectiveness
• 04.11.2025 - PRE 14A Other preliminary proxy statements
• 04.11.2025 - S-3 Registration statement under Securities Act of 1933
• 04.11.2025 - POS AM Post-Effective amendments for registration statement
• 04.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors